RE: Exciting Insights from Tim McCarthy's Interview on ImmuPharma's Future25 Jan 2025 10:21
Crazyboy,
It could be an explanation , of course ...
It's a binary situation imo because the more one goes down the 'personalised ' road , the more one limits their market potential ...
If one choses to access only patients with particulier biomarkers , then you may only have market autorisations for that 'subset' of lupus patients....
It's a vast debate, because the cost of manufacturing ' personalised medecines is extremely expensive and so the health systems find it most difficult to pay the Price in comparaison to mass manufactured pills etc ...
Anyway that's another debate , for another day ..
It would be great to see "progress" on the lupus trial asap because that is the late stage asset whilst all these " newbies " are preclinical and therefore a long road before coming to the market , imo